Similarly, a phase 1/2 study of single-agent enasidenib in patients with IDH2-mutated relapsed/refractory AML reported a CR rate of 19.6%, with similar overall response rates (ORR) among patients in relapse (38%), or who were refractory to intensive (38%) or nonintensive (43%) therapies63. Here, IDH2 is linked to acute myeloid leukemia.